Marrow T cell response after B cell targeted immunotherapy mimicking lymphoma
DOI:
https://doi.org/10.69898/jhtm.36.2026.283304บทคัดย่อ
Not required for Literature Review
Downloads
เอกสารอ้างอิง
Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-42. doi: 10.1056/NEJMoa011795. PMID: 11807147.
Onea AS, Jazirehi AR. CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas. Am J Cancer Res. 2016;6:403-24.
Ghione P, Salles G. Spotlight on polatuzumab vedotin: new standards for diffuse large B-cell lymphoma? Haematologica. 2024;109:2802-2809. doi: 10.3324/haematol.2022.282362.
Zheng R, Li Y, Shi K, Pan Y, Liu K, Song J, Li L. New horizons in B-cell lymphoma immunotherapy: From immune checkpoints to precision medicine. Neoplasia. 2025;67:101206. doi: 10.1016/j.neo.2025.101206.
Loken MR, Shah VO, Dattilio KL, Civin CI. Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development. Blood. 1987;70:1316-24. PMID: 3117132.
Chu PG, Chen YY, Molina A, Arber DA, Weiss LM. Recurrent B-cell neoplasms after Rituximab therapy: an immunophenotypic and genotypic study. Leuk Lymphoma. 2002 ;43:2335-41. doi: 10.1080/1042819021000040044. PMID: 12613521.
Lee SH, Erber WN, Porwit A, Tomonaga M, Peterson LC; International Council for Standardization In Hematology. ICSH guidelines for the standardization of bone marrow specimens and reports. Int J Lab Hematol. 2008;30:349-64. doi: 10.1111/j.1751-553X.2008.01100.x. PMID: 18822060.
Bluth RF, Casey TT, McCurley TL. Differentiation of reactive from neoplastic small-cell lymphoid aggregates in paraffin-embedded marrow particle preparations using L-26 (CD20) and UCHL-1 (CD45RO) monoclonal antibodies. Am J Clin Pathol. 1993;99:150-6. doi: 10.1093/ajcp/99.2.150. PMID: 7679873.
Sukpanichnant S, Srisook K, Chormanee N. Determination of marrow involvement in non-Hodgkin’s lymphoma by immunocytochemical studies. Siriraj Hospital Gazette. 2001;53:474-80.
Naemi K, Brynes RK, Reisian N, Johnston A, Dhillon R, Walavalkar V, Zhao X, Rezk SA. Benign lymphoid aggregates in the bone marrow: distribution patterns of B and T lymphocytes. Hum Pathol. 2013;44:512–20. doi: 10.1016/j.humpath.2012.06.012. PMID: 23063505.
Duggan PR, Easton D, Luider J, Auer IA. Bone marrow staging of patients with non-Hodgkin lymphoma by flow cytometry: correlation with morphology. Cancer. 2000;88:894-9. PMID: 10679660.
Zhang S, Wang X, Yang Z, Ding M, Zhang M, Young KH, et al. Minimal residual disease detection in lymphoma: methods, procedures and clinical significance. Front Immunol. 2024;15:1430070.
Douglas VK, Gordon LI, Goolsby CL, White CA, Peterson LC. Lymphoid aggregates in bone marrow mimic residual lymphoma after rituximab therapy for non-Hodgkin lymphoma. Am J Clin Pathol. 1999;112:844–53. doi:10.1093/ajcp/112.6.844. PMID:10587708.
Foran JM, Norton AJ, Micallef IN, Taussig DC, Amess JA, Rohatiner AZ, Lister TA. Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis. Br J Haematol. 2001;114:881-3. doi: 10.1046/j.1365-2141.2001.03019.x. PMID: 11564080.
Goteri G, Olivieri A, Ranaldi R, Lucesole M, Filosa A, Capretti R, et al. Bone marrow histopathological and molecular changes of small B-cell lymphomas after rituximab therapy: comparison with clinical response and patients' outcome. Int J Immunopathol Pharmacol. 2006;19:421–31. doi: 10.1177/039463200601900218.
Raynaud P, Caulet-Maugendre S, Foussard C, Salles G, Moreau A, Rossi JF, et al. T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy? Hum Pathol. 2008;39:194–200. doi:10.1016/j.humpath.2007.05.026. PMID:17949786.
God JM, Amria S, Cameron CA, Zhang L, Bethard JR, Haque A. B-Cell Lymphomas Secrete Novel Inhibitory Molecules That Disrupt HLA Class II-Mediated CD4+ T-Cell Recognition. Cells. 2025;14:1220. doi: 10.3390/cells14151220. PMID: 40801653; PMCID: PMC12346740.
Cortés-Romera M, Sabaté-Llobera A, Mercadal-Vilchez S, Climent-Esteller F, Serrano-Maestro A, Gámez-Cenzano C, González-Barca E. Bone marrow evaluation in initial staging of lymphoma: 18F-FDG PET/CT versus bone marrow biopsy. Clin Nucl Med. 2014;39:e46-52. doi: 10.1097/RLU.0b013e31828e9504. PMID: 23640215.
Lustberg MB, Aras O, Meisenberg BR. FDG PET/CT findings in acute adult mononucleosis mimicking malignant lymphoma. Eur J Haematol. 2008;81:154-6. doi: 10.1111/j.1600-0609.2008.01088.x. Epub 2008 May 6. PMID: 184622 Goteri G, Olivieri A, Ranaldi R, Lucesole M, Filosa A, Capretti R, et al. Bone marrow histopathological and molecular changes of small B-cell lymphomas after rituximab therapy: comparison with clinical response and patients' outcome. Int J Immunopathol Pharmacol. 2006;19:421–31. doi: 10.1177/039463200601900218.55.
Klein E, Ernberg I, Masucci MG, Szigeti R, Wu YT, Masucci G, Svedmyr E. T-cell response to B-cells and Epstein-Barr virus antigens in infectious mononucleosis. Cancer Res. 1981;41(11 Pt 1):4210-5. PMID: 6272964.
Sukpanichnant S. Reflections on how to diagnose and classify lymphoma. The International Journal of the Royal Society of Thailand 2023;XV:66-83.
ดาวน์โหลด
เผยแพร่แล้ว
ฉบับ
ประเภทบทความ
สัญญาอนุญาต
ลิขสิทธิ์ (c) 2025 วารสารโลหิตวิทยาและเวชศาสตร์บริการโลหิต
อนุญาตภายใต้เงื่อนไข Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
